EdgarLookup

Elastic N.V. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Elastic N.V. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-7.3%
Profit Margin
Net income ÷ revenue
-4.2%
Return on Assets
Net income ÷ assets
1.8x
Debt-to-Equity
Total liabilities ÷ equity
+326.9%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $1.48B Jun 10, 2025
FY2025 Jul 31, 2024 $347.42M Aug 30, 2024
FY2025 Apr 30, 2024 $1.27B Jun 10, 2025
FY2025 Jul 31, 2023 $293.75M Aug 30, 2024
FY2025 Apr 30, 2023 $1.07B Jun 10, 2025
FY2024 Apr 30, 2022 $862.37M Jun 14, 2024
FY2023 Apr 30, 2021 $608.49M Jun 16, 2023
FY2022 Apr 30, 2020 $427.62M Jun 21, 2022
FY2021 Apr 30, 2019 $271.65M Jun 25, 2021
FY2020 Apr 30, 2018 $159.94M Jun 26, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $1.10B Jun 10, 2025
FY2025 Jul 31, 2024 $255.66M Aug 30, 2024
FY2025 Apr 30, 2024 $937.24M Jun 10, 2025
FY2025 Jul 31, 2023 $216.28M Aug 30, 2024
FY2025 Apr 30, 2023 $772.36M Jun 10, 2025
FY2024 Apr 30, 2022 $630.18M Jun 14, 2024
FY2023 Apr 30, 2021 $447.44M Jun 16, 2023
FY2022 Apr 30, 2020 $304.93M Jun 21, 2022
FY2021 Apr 30, 2019 $193.64M Jun 25, 2021
FY2020 Apr 30, 2018 $119.20M Jun 26, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 ($108.11M) Jun 10, 2025
FY2025 Jul 31, 2024 ($49.23M) Aug 30, 2024
FY2025 Apr 30, 2024 $61.72M Jun 10, 2025
FY2025 Jul 31, 2023 ($48.51M) Aug 30, 2024
FY2025 Apr 30, 2023 ($236.16M) Jun 10, 2025
FY2024 Apr 30, 2022 ($203.85M) Jun 14, 2024
FY2023 Apr 30, 2021 ($129.43M) Jun 16, 2023
FY2022 Apr 30, 2020 ($167.17M) Jun 21, 2022
FY2021 Apr 30, 2019 ($102.30M) Jun 25, 2021
FY2020 Apr 30, 2018 ($52.73M) Jun 26, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 ($54.92M) Jun 10, 2025
FY2025 Jul 31, 2024 ($33.84M) Aug 30, 2024
FY2025 Apr 30, 2024 ($129.90M) Jun 10, 2025
FY2025 Jul 31, 2023 ($36.25M) Aug 30, 2024
FY2025 Apr 30, 2023 ($219.17M) Jun 10, 2025
FY2024 Apr 30, 2022 ($173.68M) Jun 14, 2024
FY2023 Apr 30, 2021 ($129.48M) Jun 16, 2023
FY2022 Apr 30, 2020 ($171.11M) Jun 21, 2022
FY2021 Apr 30, 2019 ($101.36M) Jun 25, 2021
FY2020 Apr 30, 2018 ($47.99M) Jun 26, 2020

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $365.76M Jun 10, 2025
FY2025 Jul 31, 2024 $89.33M Aug 30, 2024
FY2025 Apr 30, 2024 $341.95M Jun 10, 2025
FY2025 Jul 31, 2023 $80.69M Aug 30, 2024
FY2025 Apr 30, 2023 $313.45M Jun 10, 2025
FY2024 Apr 30, 2022 $273.76M Jun 14, 2024
FY2023 Apr 30, 2021 $199.20M Jun 16, 2023
FY2022 Apr 30, 2020 $165.37M Jun 21, 2022
FY2021 Apr 30, 2019 $101.17M Jun 25, 2021
FY2020 Apr 30, 2018 $55.64M Jun 26, 2020

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $266.17M Jun 10, 2025
FY2025 Jul 31, 2024 $52.75M Aug 30, 2024
FY2025 Apr 30, 2024 $148.76M Jun 10, 2025
FY2025 Jul 31, 2023 $37.81M Aug 30, 2024
FY2025 Apr 30, 2023 $35.66M Jun 10, 2025
FY2024 Apr 30, 2022 $5.67M Jun 14, 2024
FY2023 Apr 30, 2021 $22.55M Jun 16, 2023
FY2022 Apr 30, 2020 ($30.56M) Jun 21, 2022
FY2021 Apr 30, 2019 ($23.94M) Jun 25, 2021
FY2020 Apr 30, 2018 ($20.82M) Jun 26, 2020

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $4.35M Jun 10, 2025
FY2025 Jul 31, 2024 $747.0K Aug 30, 2024
FY2025 Apr 30, 2024 $3.45M Jun 10, 2025
FY2025 Jul 31, 2023 $632.0K Aug 30, 2024
FY2025 Apr 30, 2023 $2.68M Jun 10, 2025
FY2024 Apr 30, 2022 $2.49M Jun 14, 2024
FY2023 Apr 30, 2021 $3.91M Jun 16, 2023
FY2022 Apr 30, 2020 $5.06M Jun 21, 2022
FY2021 Apr 30, 2019 $3.45M Jun 25, 2021
FY2020 Apr 30, 2018 $2.97M Jun 26, 2020

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $2.59B Jun 10, 2025
FY2025 Jul 31, 2024 $2.15B Aug 30, 2024
FY2025 Apr 30, 2024 $2.24B Jun 10, 2025
FY2024 Apr 30, 2023 $1.74B Jun 14, 2024
FY2023 Apr 30, 2022 $1.64B Jun 16, 2023
FY2022 Apr 30, 2021 $973.17M Jun 21, 2022
FY2021 Apr 30, 2020 $803.91M Jun 25, 2021
FY2020 Apr 30, 2019 $485.74M Jun 26, 2020
FY2019 Apr 30, 2018 $183.01M Jun 28, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $1.67B Jun 10, 2025
FY2025 Jul 31, 2024 $1.39B Aug 30, 2024
FY2025 Apr 30, 2024 $1.50B Jun 10, 2025
FY2024 Apr 30, 2023 $1.34B Jun 14, 2024
FY2023 Apr 30, 2022 $1.23B Jun 16, 2023
FY2022 Apr 30, 2021 $522.34M Jun 21, 2022
FY2021 Apr 30, 2020 $390.26M Jun 25, 2021
FY2020 Apr 30, 2019 $222.73M Jun 26, 2020
FY2019 Apr 30, 2018 $135.62M Jun 28, 2019

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $927.23M Jun 10, 2025
FY2025 Jul 31, 2024 $759.42M Aug 30, 2024
FY2025 Apr 30, 2024 $738.19M Jun 10, 2025
FY2025 Jul 31, 2023 $411.72M Aug 30, 2024
FY2025 Apr 30, 2023 $398.90M Jun 10, 2025
FY2025 Apr 30, 2022 $415.43M Jun 10, 2025
FY2024 Apr 30, 2021 $450.83M Jun 14, 2024
FY2023 Apr 30, 2020 $413.65M Jun 16, 2023
FY2022 Apr 30, 2019 $263.01M Jun 21, 2022
FY2021 Apr 30, 2018 ($153.53M) Jun 25, 2021

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $319.42M Jun 10, 2025
FY2025 Jul 31, 2024 $319.42M Aug 30, 2024
FY2025 Apr 30, 2024 $319.38M Jun 10, 2025
FY2025 Apr 30, 2023 $303.64M Jun 10, 2025
FY2024 Apr 30, 2022 $303.91M Jun 14, 2024
FY2023 Apr 30, 2021 $198.85M Jun 16, 2023
FY2022 Apr 30, 2020 $197.88M Jun 21, 2022
FY2021 Apr 30, 2019 $19.85M Jun 25, 2021
FY2020 Apr 30, 2018 $19.18M Jun 26, 2020
FY2019 Apr 30, 2017 $12.06M Jun 28, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 ($1.10B) Jun 10, 2025
FY2025 Jul 31, 2024 ($1.04B) Aug 30, 2024
FY2025 Apr 30, 2024 ($991.61M) Jun 10, 2025
FY2024 Apr 30, 2023 ($1.05B) Jun 14, 2024
FY2023 Apr 30, 2022 ($817.17M) Jun 16, 2023
FY2022 Apr 30, 2021 ($613.32M) Jun 21, 2022
FY2021 Apr 30, 2020 ($484.25M) Jun 25, 2021
FY2020 Apr 30, 2019 ($317.08M) Jun 26, 2020
FY2019 Apr 30, 2018 ($214.77M) Jun 28, 2019

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $727.54M Jun 10, 2025
FY2025 Jul 31, 2024 $594.87M Aug 30, 2024
FY2025 Apr 30, 2024 $540.40M Jun 10, 2025
FY2024 Apr 30, 2023 $644.17M Jun 14, 2024
FY2023 Apr 30, 2022 $860.95M Jun 16, 2023
FY2022 Apr 30, 2021 $400.81M Jun 21, 2022
FY2021 Apr 30, 2020 $297.08M Jun 25, 2021
FY2020 Apr 30, 2019 $298.00M Jun 26, 2020
FY2019 Apr 30, 2018 $50.94M Jun 28, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 $569.73M Jun 10, 2025
FY2025 Jul 31, 2024 $568.89M Aug 30, 2024
FY2025 Apr 30, 2024 $568.61M Jun 10, 2025
FY2024 Apr 30, 2023 $567.54M Jun 14, 2024
FY2023 Apr 30, 2022 $566.52M Jun 16, 2023
FY2022 Jul 31, 2021 $565.70M Jun 21, 2022
FY2022 Apr 30, 2021 $0 Jun 21, 2022

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 (1) Jun 10, 2025
FY2025 Jul 31, 2024 0 Aug 30, 2024
FY2025 Apr 30, 2024 0 Jun 10, 2025
FY2025 Jul 31, 2023 0 Aug 30, 2024
FY2025 Apr 30, 2023 (2) Jun 10, 2025
FY2024 Apr 30, 2022 (2) Jun 14, 2024
FY2023 Apr 30, 2021 (1) Jun 16, 2023
FY2022 Apr 30, 2020 (2) Jun 21, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Apr 30, 2025 (1) Jun 10, 2025
FY2025 Jul 31, 2024 0 Aug 30, 2024
FY2025 Apr 30, 2024 0 Jun 10, 2025
FY2025 Jul 31, 2023 0 Aug 30, 2024
FY2025 Apr 30, 2023 (2) Jun 10, 2025
FY2024 Apr 30, 2022 (2) Jun 14, 2024
FY2023 Apr 30, 2021 (1) Jun 16, 2023
FY2022 Apr 30, 2020 (2) Jun 21, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2019 Apr 30, 2019 73.68M Jun 28, 2019